Moreover, in the presence of DHT, UBX‐390 treatment significantly reduced the increased levels of AR signaling‐ and prostate cancer‐related proteins, as compared to ARV‐110 treatment (Figure 2C). This evidence concerns the gene AR and prostate cancer.